Insider Scott Pittman granted AURX loan-linked warrants totaling 74,316 shares
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
Nuo Therapeutics, Inc. director and 10% owner Scott M. Pittman reported amended details for derivative awards linked to a loan arrangement. On January 23, 2026, he was granted three warrant instruments, each giving the right to buy Common Stock at an exercise price of $1.50 per share and expiring on January 23, 2031.
An integrated Initial Warrant covers 30,050 underlying shares and is immediately exercisable. A Second Warrant covers 36,750 shares and will vest, if at all, on September 30, 2026 if a Second Funding occurs under a Loan and Security Agreement dated January 21, 2026. A Prepayment Warrant covers up to 7,516 shares, vesting only upon a qualifying prepayment, but no later than December 31, 2028, under the same agreement.
The amendment primarily corrects the naming and description of the integrated Initial and Second Warrants while confirming the maximum share amounts and contingent vesting terms tied to the loan agreement.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Pittman Scott M.
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Initial Warrant (right to buy) | 30,050 | $1.50 | $45K |
| Grant/Award | Second Warrant (right to buy) | 36,750 | $1.50 | $55K |
| Grant/Award | Prepayment Warrant (right to buy) | 7,516 | $1.50 | $11K |
Holdings After Transaction:
Initial Warrant (right to buy) — 30,050 shares (Direct);
Second Warrant (right to buy) — 0 shares (Direct);
Prepayment Warrant (right to buy) — 0 shares (Direct)
Footnotes (1)
- This Form 4 amendment corrects the name of warrant issued in the form of an integrated Initial Warrant, which represents Commitment Initial, Origination Initial, and Capital Initial Warrants immediately exercisable for an aggregate of 30,050 shares of Common Stock. This Form 4 amendment corrects the name of warrant issued in the form of an integrated Second Warrant, which represents Origination Second Capital Second Warrants. Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement"). Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement. Will vest (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.
Key Figures
Initial Warrant size: 30,050 shares
Second Warrant size: 36,750 shares
Prepayment Warrant maximum: 7,516 shares
+2 more
5 metrics
Initial Warrant size
30,050 shares
Underlying Common Stock immediately exercisable at $1.50; expires January 23, 2031
Second Warrant size
36,750 shares
Underlying Common Stock; vests if Second Funding occurs on September 30, 2026; $1.50 exercise
Prepayment Warrant maximum
7,516 shares
Maximum underlying shares issuable upon Prepayment under Loan Agreement; vests by December 31, 2028
Exercise price
$1.50 per share
Conversion or exercise price for all three warrants reported on January 23, 2026
Warrant expiration
January 23, 2031
Common expiration date for the Initial, Second, and Prepayment Warrants
Key Terms
Prepayment Warrant, Initial Warrant, Second Warrant, Loan and Security Agreement, +1 more
5 terms
Prepayment Warrant financial
"Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement."
Initial Warrant financial
"integrated Initial Warrant, which represents Commitment Initial, Origination Initial, and Capital Initial Warrants immediately exercisable"
Second Warrant financial
"integrated Second Warrant, which represents Origination Second Capital Second Warrants."
Loan and Security Agreement financial
"Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto"
A loan and security agreement is a legal contract that sets out the amount, repayment schedule, interest and the rules a borrower must follow, and it names specific assets a lender can claim if the borrower fails to pay. Think of it like a mortgage or car loan where the lender holds a claim on collateral until the debt is repaid. Investors care because it determines a company’s repayment priorities, borrowing costs, operational limits and how easily creditors can seize assets in distress, all of which affect equity value and credit risk.
Second Funding financial
"Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did AURX director Scott M. Pittman report in this Form 4/A?
Scott M. Pittman reported grants of three warrant awards linked to Nuo Therapeutics stock. These include an Initial Warrant for 30,050 shares, a Second Warrant for 36,750 shares, and a Prepayment Warrant for up to 7,516 shares, all at a $1.50 exercise price.
What are the vesting conditions for Scott Pittman’s Second Warrant in Nuo Therapeutics (AURX)?
The Second Warrant for 36,750 underlying shares will vest, if at all, on September 30, 2026. Vesting requires that a Second Funding occurs under the Loan and Security Agreement dated January 21, 2026 between Nuo Therapeutics, Pittman, and other parties.
When do Scott Pittman’s Nuo Therapeutics (AURX) Prepayment Warrants vest and expire?
The Prepayment Warrant, covering up to 7,516 underlying shares, vests only upon a qualifying prepayment under the Loan Agreement, but no later than December 31, 2028. Like the other warrants, it carries an expiration date of January 23, 2031.
What corrections does this amended Nuo Therapeutics (AURX) Form 4/A make to prior warrant disclosures?
The amendment clarifies the naming and integrated nature of the Initial and Second Warrants. It explains that the Initial Warrant aggregates several initial tranches and that the Second Warrant aggregates certain second-tranche warrants, without changing the stated underlying share amounts or vesting conditions.